PPAR Vs UDCA in PBC

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive destruction of bile ducts, leading to cholestasis and liver damage. Ursodeoxycholic acid (UDCA) is the first-line treatment for PBC. However, a significant proportion of patients (approximately 30-40%) exhibit an inadequate biochemical response or intolerance to UDCA. For these patients, peroxisome proliferator-activated receptor (PPAR) agonists have emerged as promising second-line therapeutic options.

### Key Comparison: PPAR Agonists vs. UDCA in PBC

#### 1. **Effectiveness (Biochemical Response)**

• **PPAR Agonists:**
• The systematic review and network meta-analysis revealed that PPAR agonists (bezafibrate, fenofibrate, elafibranor, and seladelpar) significantly outperformed placebo and UDCA (with or without placebo) in improving biochemical markers of liver function.
• Bezafibrate ranked highest in terms of overall biochemical response, followed by seladelpar. Both agents demonstrated potent effects in reducing alkaline phosphatase (ALP) levels, a key marker of cholestasis.
• ALP normalization was most likely with bezafibrate and seladelpar, indicating robust improvement in cholestasis compared to UDCA.

• **UDCA:**
• UDCA is effective in many patients with PBC, particularly when administered early in the disease. However, for those with inadequate biochemical response, UDCA alone is insufficient to prevent disease progression or improve long-term outcomes.

#### 2. **Safety and Tolerability**

• **PPAR Agonists:**
• PPAR agonists were generally well-tolerated, with rare adverse event-related discontinuations observed across the studies.
• No significant safety concerns were identified, and reductions in ALP and bilirubin levels were consistent regardless of baseline disease severity.
• Bezafibrate and seladelpar demonstrated favorable safety profiles, making them attractive options for long-term use.

• **UDCA:**
• UDCA is also well-tolerated in most patients, but some may experience gastrointestinal side effects or intolerance, necessitating alternative therapies.

#### 3. **Mechanism of Action**

• **PPAR Agonists:**
• PPAR agonists target nuclear receptors (PPAR-α, PPAR-δ, and PPAR-γ) that regulate lipid metabolism, inflammation, and bile acid homeostasis. This dual action helps reduce cholestasis and liver inflammation, addressing key pathological processes in PBC.
• Bezafibrate and fenofibrate are primarily PPAR-α agonists, while seladelpar is a selective PPAR-δ agonist, and elafibranor is a dual PPAR-α/δ agonist.

• **UDCA:**
• UDCA works by reducing bile acid toxicity, improving bile flow, and exerting anti-inflammatory effects. However, its mechanism does not directly address the metabolic and inflammatory pathways targeted by PPAR agonists.

#### 4. **Clinical Implications**

• **PPAR Agonists as Second-Line Therapy:**
• For patients with inadequate or intolerant response to UDCA, PPAR agonists provide an effective second-line option, with bezafibrate and seladelpar emerging as leading choices based on biochemical outcomes.
• These agents offer a complementary mechanism of action to UDCA, making combination therapy a potential strategy for optimizing treatment in PBC.

• **UDCA as First-Line Therapy:**
• UDCA remains the standard initial therapy for PBC due to its proven efficacy in many patients and its long history of use. However, its limitations in non-responders highlight the need for additional therapeutic options like PPAR agonists.

#### 5. **Research and Future Directions**

• The findings of the systematic review emphasize the need for head-to-head clinical trials comparing PPAR agonists directly to UDCA and to each other. This would provide more definitive evidence on their relative efficacy, safety, and long-term benefits.
• Investigating the impact of PPAR agonists on patient-centered outcomes (e.g., quality of life, symptom relief, and long-term disease progression) is also a critical area for future research.

### Conclusion

PPAR agonists represent a significant advancement in the management of PBC, particularly for patients who do not adequately respond to UDCA. Bezafibrate and seladelpar stand out as the most effective options based on biochemical outcomes, with good safety and tolerability profiles. While UDCA remains the cornerstone of first-line therapy, PPAR agonists offer a valuable second-line strategy to improve outcomes in this challenging patient population.